Kilitch Drugs (India) Limited (NSE:KILITCH)
India · Delayed Price · Currency is INR 220.00
-1.62 (-0.73%)
Sep 24, 2026, 2:43 PM IST
Kilitch Drugs (India) Revenue
Kilitch Drugs (India) had revenue of 448.79M INR in the quarter ending June 30, 2026, with 4.03% growth. This brings the company's revenue in the last twelve months to 2.37B, up 14.04% year-over-year. In the fiscal year ending March 31, 2026, Kilitch Drugs (India) had annual revenue of 2.35B with 18.74% growth.
Revenue (ttm)
2.37B
Revenue Growth
+14.04%
P/S Ratio
3.30
Revenue / Employee
10.05M
Employees
236
Market Cap
7.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.35B | 371.56M | 18.74% |
| Mar 31, 2025 | 1.98B | 439.46M | 28.47% |
| Mar 31, 2024 | 1.54B | 147.74M | 10.58% |
| Mar 31, 2023 | 1.40B | 253.65M | 22.20% |
| Mar 31, 2022 | 1.14B | 457.11M | 66.71% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.73B |
| Windlas Biotech | 9.42B |
| Sigachi Industries | 4.71B |
| Beta Drugs | 4.10B |
| Valiant Laboratories | 3.06B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Amanta Healthcare | 2.91B |
| Sakar Healthcare | 2.72B |
Kilitch Drugs (India) News
- 1 year ago - Kilitch Drugs India shares surge over 2% as company invests $200,000 in Kilitch Estro Biotech - Business Upturn